Amgen announced new data from a 12,000-patient trial showing that its cholesterol-lowering drug Repatha (a PCSK9 inhibitor) effectively reduces the risk of death from cardiovascular disease, heart attacks, and strokes in patients without prior cardiac events. This primary prevention finding could expand Repatha's market significantly beyond those with existing heart disease. The drug works by lowering LDL cholesterol, a key factor in atherosclerosis. Sales of Repatha have been rising, signaling renewed commercial success in a drug class that once struggled commercially.